Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label, Phase 1 Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors

NCT07327632 is registered in ClinicalTrials.gov with Innovent Biologics Technology Limited (Shanghai R&D Center) as lead sponsor.

NCT NCT07327632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07327632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label, Phase 1 Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
Lead sponsor
Innovent Biologics Technology Limited (Shanghai R&D Center)
Phase
Phase 1
Overall status
Recruiting
Start date
January 29, 2026
Completion date
December 31, 2028
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor